Effects of intracerebroventricular injection of Delta Sleep-Inducing Peptide (DSIP) and an analogue on sleep and brain temperature in rats at night

Obál, F.; Török, Angela; Alföldi, P.; Sáry, Gyula; Hajós, Mihály; Penke, Botond

doi:10.1016/0091-3057(85)90099-1

Cited by 11 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DSIP has been previously thought to be a sleep-induc ing peptide, specifically stimulating delta sleep [10][11][12][13], although some studies have not confirmed that adminis tration of this peptide does indeed increase delta sleep [31][32][33]. We have recently shown a distinct diurnal rhythm for plasma DSIP-LI, with highest levels in the late afternoon and evening and decreased levels after turning off the lights and allowing sleep to occur [22], Plasma DSIP-LI levels were found to be substantially lower in REM sleep and somewhat lower in delta sleep.…”

Section: Discussionmentioning

confidence: 99%

Decreased Delta-Sleep and Plasma Delta-Sleep-Inducing Peptide in Patients with Cushing Syndrome

et al. 1994

View full text Add to dashboard Cite

To evaluate the sleep disturbances of patients with Cushing syndrome and to examine the relationship between the sleep disturbances and plasma levels of delta-sleep-inducing peptide-like immunoreactivity (DSIP-LI), we performed three polysomnographic/endocrinological studies in patients with Cushing syndrome. In study 1, polysomnography was studied in 12 patients and 12 matched normal volunteers. In addition, DSIP-LI was measured every 30 min for 24 h in 9 patients with Cushing syndrome and 12 normal volunteers. The percentage of time spent in delta sleep (stages 3 and 4) was significantly reduced in patients with Cushing syndrome (5.8 ± 1.4%; mean ± SEM) compared to normal volunteers (14.0 ± 2.5%) (p < 0.01). REM sleep indices, however, were not significantly different between the two groups. There was a significant negative correlation between amount of delta sleep and 08.00 h DSIP-LI (r = –0.43, p < 0.05), which is against the notion of a causal relationship between DSIP-LI and delta sleep. The circadian rhythm of plasma DSIP-LI was found to be similar in Cushing patients and normal volunteers. In study 2, we measured plasma levels of delta-sleep-inducing peptide-like immunoreactivity (DSIP-LI) at 08.00 h in 65 patients with Cushing syndrome and 49 normal volunteers. The 08.00 h DSIP-LI concentrations of 797 ± 57 pmol/l (mean ± SEM) in the patients with Cushing syndrome were significantly reduced compared to the level of 1,062 ± 99 pmol/l found in the normal volunteers (p < 0.05). In study 3, plasma was drawn simultaneously from the petrosal sinuses and peripheral veins of Cushing patients. No central-to-peripheral gradient for plasma DSIP-LI was noted and neither peripheral, nor central plasma DSIP-LI was affected by administration of intravenous ovine CRH. We conclude that patients with Cushing syndrome have less delta sleep and lower plasma concentrations of DSIP-LI than normal controls, however a causal relationship between the two appears to be unlikely. The pituitary does not appear to be the site of synthesis of plasma DSIP, whose source remains unknown.

show abstract

Section: Discussionmentioning

confidence: 99%

Decreased Delta-Sleep and Plasma Delta-Sleep-Inducing Peptide in Patients with Cushing Syndrome

et al. 1994

View full text Add to dashboard Cite

show abstract

“…21 There are published reports, where no sleep inducing effect (in some case wake inducing) of DSIP was found in rabbits after IV injection,27 in cats after IP injection 92 and in rats after ICV injection. 73 Brain temperature in the rats was not affected and an analog, co-amino-caprilyl DSIP, also failed to change any of these parameters. Rather an increase in wakefulness was observed after the injection of either peptide.…”

Section: Delta Sleep-inducing Peptidementioning

confidence: 90%

Sleep-Inducing Substances in the Regulation of Sleep

Ramesh

Kaushal

Kumar

2006

Neuroendocrine Correlates of Sleep/Wakefulness

View full text Add to dashboard Cite

“…1995), and especially on sleep. A number of studies failed to confirm SWS‐ or PS‐promoting properties of DSIP, as well as an increase in the EEG spectrum delta power, after either introcerebroventricular (ICV) or systemic administration of DSIP; only minor effects were found in others, and even an impairment of sleep has been reported (Schneider‐Helmert and Shoenenberger 1983; Obál et al . 1985; Kovalzon 1986, 1994, 1999; Obál et al .…”

Section: Structure Of Delta Sleep‐inducing Peptide (Dsip) and Dermorpmentioning

confidence: 99%

Delta sleep‐inducing peptide (DSIP): a still unresolved riddle

Kovalzon

Strekalova

2006

Journal of Neurochemistry

View full text Add to dashboard Cite

Delta sleep-inducing peptide (DSIP) was isolated from rabbit cerebral venous blood by Schoenenberger-Monnier group from Basel in 1977 and initially regarded as a candidate sleep-promoting factor. However, the link between DSIP and sleep has never been further characterized, in part because of the lack of isolation of the DSIP gene, protein and possible related receptor. Thus the hypothesis regarding DSIP as a sleep factor is extremely poorly documented and still weak. Although DSIP itself presented a focus of study for a number of researchers, its natural occurrence and biological activity still remains obscure. DSIP structure is different from any other known representative of the various peptide families. In this mini-review we hypothesize the existence of a DSIP-like peptide(s) that is responsible (at least partly) for DSIP-like immunoreactivity and DSIP biological activity. This assumption is based on: (i) a highly specific distribution of DSIP-like immunoreactivity in the neurosecretory hypothalamic nuclei of various vertebrate species that are not particularly relevant for sleep regulation, as revealed by the histochemical studies of the Geneva group (Charnay et al.); (ii) a large spectrum of DSIP biological activity revealed by biochemical and physiological studies in vitro; (iii) significant slow-wave sleep (SWS) promoting activity of certain artificial DSIP structural analogues (but not DSIP itself!) in rabbits and rats revealed by our early studies; and (iv) significant SWS-promoting activity of a naturally occurring dermorphin-decapeptide that is structurally similar to DSIP (in five of the nine positions) and the sleep-suppressing effect of its optical isomer, as revealed in rabbits. Potential future studies are outlined, including natural synthesis and release of this DSIP-like peptide and its role in neuroendocrine regulation.

show abstract

Effects of intracerebroventricular injection of Delta Sleep-Inducing Peptide (DSIP) and an analogue on sleep and brain temperature in rats at night

Cited by 11 publications

References 27 publications

Decreased Delta-Sleep and Plasma Delta-Sleep-Inducing Peptide in Patients with Cushing Syndrome

Decreased Delta-Sleep and Plasma Delta-Sleep-Inducing Peptide in Patients with Cushing Syndrome

Sleep-Inducing Substances in the Regulation of Sleep

Delta sleep‐inducing peptide (DSIP): a still unresolved riddle

Contact Info

Product

Resources

About